Added to YB: 2025-10-21
Pitch date: 2025-10-17
GSK [neutral]
GSK plc
+13.48%
current return
Author Info
No bio for this author
Company Info
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally.
Market Cap
GBP 72.9B
Pitch Price
GBP 16.08
Price Target
N/A
Dividend
3.36%
EV/EBITDA
8.93
P/E
13.65
EV/Sales
2.70
Sector
Pharmaceuticals
Category
value
Theodosian Capital | GSK – Pipeline progress
GSK (update): China approved Shingrix for immunocompromised adults 18+, expanding addressable market beyond 50+ age group in country with ~6M annual shingles cases. 66 vaccines/medicines in Phase I-III pipeline. Trades at cheap 9.1x 2026 consensus earnings, 4.3% yield.
Read full article (1 min)